

Supporting Information

Kratzer et al. 10.1073/pnas.1320393111




Fig. S1. Branch mutations that occur between An19/22 and the human uricase were individually inserted in An19/22 and assayed. Each of the 22 amino acid replacements (the number of replacements between An19/22 and the human uricase pseudogene) were assayed within the context of the An19/22 ancient protein to better understand the effects of individual mutations during mammalian uricase history. Each variant was characterized by the following properties: (i) the specific enzyme activity of the purified tetrameric variant (purple) and (ii) catalytic efficiency (i.e., k_{cat}/K_m) of the purified tetrameric variant (blue). All reported values are relative to the ancestral An19/22 enzyme. Two amino acid replacements, F222S and Y240C, prevented the purification of An19/22 variants and therefore their activity was not determined. The single S232L replacement could be purified, but its relative activity was severely diminished. Fig. 1 provides node numbers and branches.




Fig. 54. Representative Western blot of lysates from HepG2 cells stably expressing an empty vector control or An27. ACC, Acetyl-Coa carboxylase; AMPK, AMP kinase; P, phosphorylated protein.

		10	20	30	40	50	60
PBC	MAHYRNDYK	NDEVEFVRTG	YGKDMIKVLH	IQRDGKYHSI	KEVATSVQLT	LSSKKDYLHG	
An19/22	MAHYHNDYK	NDEVEFVRTG	YGKDMVKVLH	IQRDGKYHSI	KEVATSVQLT	LSSKKDYLHG	
An26	MAHYHNDYK	NDEVEFVRTG	YGKDMVKVLH	IQRDGKYHSI	KEVATSVQLT	LSSKKDYLHG	
An27	MAHYHNNYK	NDEVEFVRTG	YGKDMVKVLH	IQRDGKYHSI	KEVATSVQLT	LSSKKDYLHG	
An30	MAHYHNNYK	NDEVEFVRTG	YGKDMVKVLH	IQRDGKYHSI	KEVATSVQLT	LSSKKDYLHG	
An31	MAHYHNNYK	NDEVEFVRTG	YGKDMVKVLH	IQRDGKYHSI	KEVATSVQLT	LSSKKDYLHG	
An32/33	MAHYHNNYK	NDEVEFVRTG	YGKDMVKVLH	IQRDGKYHSI	KEVATSVQLT	LSSKKDYLHG	
		70	80	90	100	110	120
PBC	DNSDVIPTDT	IKNTVNVLAK	FKGIKSIETF	AVTICEHFLS	SFKHVIRAQV	YVEEVPWKR	F
An19/22	DNSDIPTDT	IKNTVHVLAK	FKGIKSIEAF	AMNICEHFLS	SFNHVIRAQV	YVEEVPWKR	F
An26	DNSDIPTDT	IKNTVHVLAK	FKGIKSIEAF	AVNICEHFLS	SFNHVIRAQV	YVEEIPWKR	L
An27	DNSDIPTDT	IKNTVHVLAK	FKGIKSIEAF	GVNICEHFLS	SFNHVIRAQV	YVEEIPWKR	L
An30	DNSDIPTDT	IKNTVHVLAK	FKGIKSIEAF	GVNICEHFLS	SFNHVIRAQV	YVEEIPWKR	L
An31	DNSDIPTDT	IKNTVHVLAK	FKGIKSIEAF	GVNICEHFLS	SFNHVIRAQV	YVEEIPWKR	L
An32/33	DNSDIPTDT	IKNTVHVLAK	FKEIKSIEAF	GVNICEHFLS	SFNHVIRAQV	YVEEIPWKR	H
		130	140	150	160	170	180
PBC	EKNGVKHVHA	FIYTPGTGHF	CEVEQIRNGP	PVIHSGIKDL	KVLKTTQSGF	EGFIKDQFTT	
An19/22	EKNGVKHVHA	FIHTPTGTHF	CEVEQMRS GP	PVIHSGIKDL	KVLKTTQSGF	EGFIKDQFTT	
An26	EKNGVKHVHA	FIHTPTGTHF	CEVEQLRSGP	PVIHSGIKDL	KVLKTTQSGF	EGFIKDQFTT	
An27	EKNGVKHVHA	FIHTPTGTHF	CEVEQLRSGP	PVIHSGIKDL	KVLKTTQSGF	EGFIKDQFTT	
An30	EKNGVKHVHA	FIHTPTGTHF	CEVEQLRSGP	PVIHSGIKDL	KVLKTTQSGF	EGFIKDQFTT	
An31	EKNGVKHVHA	FIHTPTGTHF	CEVEQLRSGP	PVIHSGIKDL	KVLKTTQSGF	EGFIKDQFTT	
An32/33	EKNGVKHVHA	FIHTPTGTHF	CEVEQLRSGP	QVIHSGIKDL	KVLKTTQSGF	EGFIKDQFTT	
		190	200	210	220	230	240
PBC	LPEVKDRCFA	TQVYCKWRYH	QGRDVFDEAT	WDTVRSIVLQ	KFAGPYDKGE	YSPSVQKTLY	
An19/22	LPEVKDRCFA	TQVYCKWRYH	QGRDVFDEAT	WDTV RDIVLE	KFAGPYDKGE	YSPSVQKTLY	
An26	LPEVKDRCFA	TQVYCKWRYH	QCRDVFDEAT	WDTIRDLVLE	KFAGPYDKGE	YSPSVQKTLY	
An27	LPEVKDRCFA	TQVYCKWRYH	QCRDVFDEAT	WDTIRDLVLE	KFAGPYDKGE	YSPSVQKTLY	
An30	LPEVKDRCFA	TQVYCKWRYH	QCRDVFDEAT	WDTIRDLVLE	KSAGPYDKGE	YSPSVQKTLY	
An31	LPEVKDRCFA	TQVYCKWRYH	QCRDVFDEAT	WDTIRDLVLE	KSAGPYDKGE	YSPSVQKTLY	
An32/33	LPEVKDRCFA	TQVYCKWRYH	QCRDVFDEAT	WDTIRDLVME	KSAGPYDKDE	YSPSVQKTLC	
		250	260	270	280	290	300
PBC	DIQVLSLSRV	PEIEDMEISL	PNIHYFNIDM	SKMGLINKEE	VLLPLDNPYG	KITGTV KRKL	
An19/22	DIQVLSLSRV	PEIEDMEISL	PNIHYFNIDM	SKMGLINKEE	VLLPLDNPYG	KITGTV KRKL	
An26	DIQVLSLSRV	PEIEDMEISL	PNIHYFNIDM	SKMGLINKEE	VLLPLDNPYG	KITGTV KRKL	
An27	DIQVLSLSRV	PEIEDMEISL	PNIHYFNIDM	SKMGLINKEE	VLLPLDNPYG	KITGTV KRKL	
An30	DIQVLSLSRV	PEIEDMEISL	PNIHYFNIDM	SKMGLINKEE	VLLPLDNPYG	KITGTV KRKL	
An31	DIQVLSLSRV	PEIEDMEISL	PNIHYFNIDM	SKMGLINKEE	VLLPLDNPYG	KITGTV KRKL	
An32/33	DIQVLSLSRV	PAIEDMEISL	PNIHYFNIDM	SKMGLINKEE	VLLPLDNPYG	KITGTV KRKL	
PBC	SSRL						
An19/22	SSRL						
An26	SSRL						
An27	SSRL						
An30	SSRL						
An31	SSRL						
An32/33	SSRL						

Fig. S5. Ancestral and chimera uricase amino acid sequences. The aligned sequences are labeled according to Fig. 1 in the article and shown in 10-residue blocks. Each sequence is 304 aa long. Also shown is the pig-baboon chimera (PBC) uricase that represents the protein component of the US Food and Drug Administration-approved pegloticase and is included in this alignment for reference. Residues that differ from the human pseudogene are highlighted in gray (except for the two premature stop codons at position 33 and 187).




Fig. 56. Healthy rats injected with An19/22 displayed enhanced pharmacokinetics compared with the PBC uricase. Ten male Sprague–Dawley rats (five rats for each uricase) were each injected with 1 mL (0.2 mg/mL) of recombinant uricase preparations (An19/22 and PBC, the non-PEGylated form of pegloticase). One milliunit is the amount of uricase needed to oxidize 1 nM of urate per minute under assay conditions. The An19/22 uricase has a longer $t_{1/2}$ compared with PBC uricase. A Student *t* test was performed with a *P* value of 0.02.




Fig. S9. Phylogram of uricases generated from a codon-based maximum likelihood analysis. The internal nodes are labeled with the posterior probability, a measure of statistical support, for each ancestral sequence inferred (note that these values are not nodal support). This phylogeny follows the inferred species tree for these organisms. The scale bar represents 0.2 replacements per site per unit evolutionary time. GenBank Identifier (GI) numbers are provided after each common species name.

